<svg xmlns="http://www.w3.org/2000/svg" width="1768" height="994" viewBox="0 0 1768 994"><g transform="translate(-100 -54)"><text transform="translate(100 100)" fill="#007a33" font-size="52" font-family="Trade Gothic LT Std Extended, Trade Gothic LT Std" font-weight="700"><tspan x="0" y="38">Reduce their use of IV iron</tspan></text><text transform="translate(100 958)" fill="#4d4d4f" font-size="21" font-family="TradeGothicLTStd, Trade Gothic LT Std"><tspan x="0" y="15">1. Barratt J et al. Nephrol Dial Transplant. 2021;36(9):1616–1628. </tspan><tspan x="0" y="44">2. Barratt J et al. Nephrol Dial Transplant. 2021;36(9):1616–1628 (Supplement).</tspan><tspan x="0" y="73">3. EVRENZO EU SmPC, July 2022.</tspan></text><text transform="translate(100 187)" fill="#4d4d4f" font-size="32" font-weight="bold" font-family="Trade Gothic LT Std, Trade Gothic LT Std"><tspan x="0" y="23">Fewer NDD patients on EVRENZO were treated with IV iron than those treated with ESA</tspan><tspan y="23" font-size="18.666" baseline-shift="10.66559989886036">1</tspan></text><text transform="translate(1238 426)" fill="#4d4d4f" font-size="27" font-family="TradeGothicLTStd, Trade Gothic LT Std"><tspan x="0" y="19">EVRENZO achieved serum iron levels</tspan><tspan x="0" y="56">comparable to ESA,</tspan><tspan y="56" font-size="15.749" baseline-shift="8.999099846546754">2</tspan><tspan y="56" xml:space="preserve"> but with less use of IV iron </tspan><tspan x="0" y="93">compared with ESA</tspan><tspan y="93" font-size="15.749" baseline-shift="8.999099846546754">1</tspan><tspan x="0" y="130">EVRENZO was effective without routine use of IV </tspan><tspan x="0" y="167">iron in most patients</tspan><tspan y="167" font-size="15.749" baseline-shift="8.999099846546754">1</tspan><tspan x="0" y="204"></tspan></text><text transform="translate(1238 687)" fill="#4d4d4f" font-size="27" font-family="TradeGothicLTStd, Trade Gothic LT Std"><tspan x="0" y="19">Fewer IV iron infusions were administered in </tspan><tspan x="0" y="56">patients treated with EVRENZO than those </tspan><tspan x="0" y="93">treated with ESA</tspan><tspan y="93" font-size="15.749" baseline-shift="8.999099846546754">3</tspan><tspan x="0" y="130"></tspan></text><text transform="translate(1218 384)" fill="#4d4d4f" font-size="27" font-weight="bold" font-family="Trade Gothic LT Std, Trade Gothic LT Std"><tspan x="0" y="19">In patients not on dialysis:</tspan></text><text transform="translate(1218 426)" fill="#007a33" font-size="27" font-family="TradeGothicLTStd, Trade Gothic LT Std"><tspan x="0" y="19">• </tspan></text><text transform="translate(1218 538)" fill="#007a33" font-size="27" font-family="TradeGothicLTStd, Trade Gothic LT Std"><tspan x="0" y="19">• </tspan></text><text transform="translate(1218 685)" fill="#007a33" font-size="27" font-family="TradeGothicLTStd, Trade Gothic LT Std"><tspan x="0" y="19">• </tspan></text><rect width="1028" height="690" rx="43" transform="translate(100 233)" fill="#fff" opacity="0.612"/><g transform="translate(256.215 416.157)"><text transform="translate(647.785 158.089)" fill="#006345" font-size="24" font-weight="bold" font-family="Trade Gothic LT Std, Trade Gothic LT Std"><tspan x="0" y="17">NDD vs. active </tspan><tspan x="0" y="43.01">comparator:</tspan><tspan fill="#e29a40"><tspan x="0" y="69.02">DOLOMITES</tspan></tspan></text><g transform="translate(648.925 47.843)"><path d="M713.944,61.267l38.274,66.293H675.67Zm26.088,59.258L713.944,75.338l-26.089,45.188Z" transform="translate(-606.034 -27.194)" fill="#e29a40"/><path d="M706.181,47.843l57.946,100.366H648.234Zm45.76,93.331-45.76-79.26-45.761,79.26Z" transform="translate(-648.234 -47.843)" fill="#006345"/></g></g><text transform="translate(1218 647)" fill="#4d4d4f" font-size="27" font-weight="bold" font-family="Trade Gothic LT Std, Trade Gothic LT Std"><tspan x="0" y="19">In patients on dialysis:</tspan></text><text transform="translate(178 875)" fill="#4d4d4f" font-size="21" font-family="TradeGothicLTStd, Trade Gothic LT Std"><tspan x="0" y="15" xml:space="preserve"> Use of IV iron was a secondary endpoint</tspan></text><g transform="translate(1083 -6008.75)"><text transform="translate(-905 6293.694)" fill="#4d4d4f" font-size="27" font-weight="bold" font-family="Trade Gothic LT Std, Trade Gothic LT Std"><tspan x="0" y="19">Number of patients treated with IV iron (%)</tspan><tspan y="19" font-size="15.749" baseline-shift="8.999099846546754">1</tspan></text><g transform="translate(-903.703 6360.907)"><text transform="translate(73.394 271.923)" fill="#666" font-size="12" font-family="Trade Gothic LT Std Extended, Trade Gothic LT Std" font-weight="700"><tspan x="-17.328" y="0">20</tspan></text><text transform="translate(73.394 358.156)" fill="#666" font-size="12" font-family="Trade Gothic LT Std Extended, Trade Gothic LT Std" font-weight="700"><tspan x="-17.328" y="0">10</tspan></text><text transform="translate(73.394 99.716)" fill="#666" font-size="12" font-family="Trade Gothic LT Std Extended, Trade Gothic LT Std" font-weight="700"><tspan x="-17.328" y="0">40</tspan></text><text transform="translate(73.394 185.692)" fill="#666" font-size="12" font-family="Trade Gothic LT Std Extended, Trade Gothic LT Std" font-weight="700"><tspan x="-17.328" y="0">30</tspan></text><text transform="translate(73.026 11.017)" fill="#666" font-size="12" font-family="Trade Gothic LT Std Extended, Trade Gothic LT Std" font-weight="700"><tspan x="-17.328" y="0">50</tspan></text><text transform="translate(75.85 444.905)" fill="#666" font-size="12" font-family="Trade Gothic LT Std Extended, Trade Gothic LT Std" font-weight="700"><tspan x="-8.664" y="0">0</tspan></text><text transform="translate(12 224.129) rotate(-90)" fill="#666" font-size="16" font-family="Trade Gothic LT Std Extended, Trade Gothic LT Std" font-weight="700"><tspan x="-102.872" y="0">Number of patients (%)</tspan></text><text transform="translate(279.754 477.899)" fill="#666" font-size="16" font-family="Trade Gothic LT Std Extended, Trade Gothic LT Std" font-weight="700"><tspan x="-48" y="0">EVRENZO</tspan><tspan x="-32.792" y="19">(n=322)</tspan></text><text transform="translate(511.093 477.899)" fill="#666" font-size="16" font-family="Trade Gothic LT Std Extended, Trade Gothic LT Std" font-weight="700"><tspan x="-20" y="0">ESA</tspan><tspan x="-32.792" y="19">(n=292)</tspan></text><line y1="434.317" transform="translate(88.525 7.648)" fill="none" stroke="#666" stroke-miterlimit="10" stroke-width="2"/><line x1="645.076" transform="translate(87.721 441.965)" fill="none" stroke="#666" stroke-miterlimit="10" stroke-width="2"/><text transform="translate(324.543 0)" font-size="17" font-family="TradeGothicLTStd, Trade Gothic LT Std"><tspan x="-33.193" y="12">p=0.004</tspan></text></g><g transform="translate(-677.847 6386.971)"><text transform="translate(56.79 234.089)" fill="#2a4934" font-size="16" font-family="Trade Gothic LT Std Extended, Trade Gothic LT Std" font-weight="700"><tspan x="-34.208" y="0">20 (6.2)</tspan></text><rect width="128.209" height="171.165" transform="translate(0 244.735)" fill="#2a4934"/><path d="M453,650.372V448.237H677.709v51.369" transform="translate(-388.892 -448.237)" fill="none" stroke="#707070" stroke-width="1"/></g><g transform="translate(-452.471 6450.841)"><text transform="translate(55.847 12)" fill="#75777a" font-size="16" font-family="Trade Gothic LT Std Extended, Trade Gothic LT Std" font-weight="700"><tspan x="-39.984" y="0">37 (12.7)</tspan></text><rect width="128.209" height="327.169" transform="translate(0 24.861)" fill="#75777a"/></g></g><g transform="translate(1251.124 -255.085)"><text transform="translate(210.876 310.085)" fill="#4d4d4f" font-size="21" font-weight="bold" font-family="Trade Gothic LT Std, Trade Gothic LT Std"><tspan x="0" y="15">This information is intended for </tspan><tspan x="0" y="40">international audiences.</tspan></text></g><text transform="translate(1462 118)" fill="#4d4d4f" font-size="21" font-weight="bold" font-family="Trade Gothic LT Std, Trade Gothic LT Std"><tspan x="0" y="15">EVRENZO (roxadustat) IS NOT APPROVED </tspan><tspan x="0" y="40">FOR USE IN THE UNITED STATES</tspan></text></g></svg>